Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS: Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS: Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (−8.5 vs. −0.05%; P < 0.01) than those assigned to DSE and had a greater decline in steatosis (−50.8 vs. −22.8%; P = 0.04) and in A1C (−0.7 vs. −0.2%; P = 0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P < 0.05). CONCLUSIONS: A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, histological improvement of different MASLD components depended on the amount of weight loss: Whereas about 5-7 % of weight loss already lead to a reduction in liver lipid content in 65 % of people with MASLD, MASH resolution (defined as the absence of hepatocellular ballooning) was achieved in 64 % by a 7-10 % decrease in body weight [46][47][48][49].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a 12‐month lifestyle intervention program in patients with type 2 diabetes, hepatic steatosis and incident NAFLD was significantly reduced [28].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Obesity, diabetes, and insulin resistance are the main risk factors for more advanced forms of the disease; up to 70–80% of individuals with NAFLD have insulin resistance or metabolic syndrome (3).”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cited by
Items 101–200 of 366
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
“However, because greater weight loss has been associated with greater health improvements (48-57), individuals who are interested in achieving greater weight loss goals should also be informed of the efforts required to do so.”
BackgroundNutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
Conlon, B., Beasley, J., Aebersold, K., Jhangiani, S., & Wylie-Rosett, J. (2013) · Nutrients · doi:10.3390/nu5104093 · Cited by 72
“The Fatty Liver Ancillary Study of the Look AHEAD (Action for Health in Diabetes) trial [46] observed individuals randomized to receive 1-year of treatment to an intensive lifestyle intervention (ILI) group (moderate caloric restriction, <30% fat of total energy, increased physical activity, weight loss goal of 7% bod…”
BackgroundMethodNon-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment
Oh, H., Jun, D. W., Saeed, W. K., & Nguyen, M. H. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.0049 · Cited by 76
“A minimum of 5% weight loss decreases hepatic fat, and a 7-10% weight loss is required to improve hepatic inflammation.(42,43) However, it is difficult for diet and exercise regimens to achieve and maintain a 10% weight loss.”
BackgroundGLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 76
Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease
Stine, J. G., Soriano, C., Schreibman, I., Rivas, G., Hummer, B., Yoo, E., Schmitz, K., & Sciamanna, C. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06673-w · Cited by 70
Brouwers, B., Schrauwen-Hinderling, V. B., Jelenik, T., Gemmink, A., Sparks, L. M., Havekes, B., Bruls, Y., Dahlmans, D., Roden, M., Hesselink, M. K. C., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00266.2017 · Cited by 69
Malin, S. K., Mulya, A., Fealy, C. E., Haus, J. M., Pagadala, M. R., Scelsi, A. R., Huang, H., Flask, C. A., McCullough, A. J., & Kirwan, J. P. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00237.2013 · Cited by 68
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 75
“Therefore, in 2010, FDA withdrew sibutramine from the US market due to risk of serious cardiovascular events [92] and many studies with sibutramine were discontinued due to adverse effects [93].”
BackgroundGarvey, W. T. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2021.11.082 · Cited by 66
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P., Candia, R., Zapata, R., Muñoz, C., Arancibia, J. P., Poniachik, J., Soza, A., Fuster, F., Brahm, J., Sanhueza, E., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 71
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Belalcazar, L. M., Haffner, S. M., Lang, W., Hoogeveen, R. C., Rushing, J., Schwenke, D. C., Tracy, R. P., Pi‐Sunyer, F. X., Kriska, A. M., & Ballantyne and the Look AHEAD (Action for Health in Diabetes, C. M. (2013) · Obesity · doi:10.1002/oby.20431 · Cited by 63
“Although statins may have a predominant effect on hepatic production of CRP (32) and ILI a potentially greater impact on adipose-derived CRP in the setting of obesity (33,34), it is possible that statin use and ILI affect production at both sites (35-38).”
BackgroundSelf-citationExercising the hepatobiliary‐gut axis. The impact of physical activity performance
Molina‐Molina, E., Baccetto, R., Wang, D. Q. ‐., de Bari, O., Krawczyk, M. J., & Portincasa, P. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12958 · Cited by 70
Weight reduction for non-alcoholic fatty liver disease
Peng, L., Wang, J., & Li, F. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003619.pub3 · Cited by 61
Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment
Rahimi, R. S., & Landaverde, C. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533612470464 · Cited by 61
Wong, C., Yaow, C. Y. L., Ng, C. H., Chin, Y. H., Low, Y. F., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.609135 · Cited by 69
“3% improvement in hepatic steatosis (64).”
Otgonsuren, M., Stepanova, M., Gerber, L. H., & Younossi, Z. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2446-3 · Cited by 64
Physical activity: an essential component of lifestyle modification in NAFLD
Rodriguez, B., Torres, D. M., & Harrison, S. A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.200 · Cited by 72
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59
The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis
Mazzoccoli, G., Cosmo, S. D., & Mazza, T. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00193 · Cited by 66
“…3–5% of weight loss, achieved by hypocaloric diet alone or in combination with physical activity and behavioral modification, commonly diminishes hepatic steatosis, whilst at least 10% of weight loss may be needed to ameliorate hepatic necroinflammation (Lazo et al., 2010; Fan and Cao, 2013).”
BackgroundWatanabe, M., Risi, R., Camajani, E., Contini, S., Persichetti, A., Tuccinardi, D., Ernesti, I., Mariani, S., Lubrano, C., Genco, A., et al. (2020) · Nutrients · doi:10.3390/nu12072141 · Cited by 62
“Interestingly, the Look AHEAD (Action for Health in Diabetes) study demonstrated that weight loss reduces liver fat in a non-linear fashion, as 5% weight loss reduces NMR-measured intrahepatic triglyceride content by 13%; 11% weight loss reduces it by 52% and 16% by 65%, with the greatest reduction in those undergoing…”
BackgroundResultYang, W., Liu, L., Wei, Y., Fang, C., Liu, S., Zhou, F., Li, Y., Zhao, G., Guo, Z., Luo, Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00508-y · Cited by 60
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations
Richard, J., & Lingvay, I. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.15 · Cited by 57
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“Ad-ditionally, they exhibited a more substantial reduction in hepatic steatosis [68].”
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sanchez, P., & Cusi, K. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 56
“content (and improvement in cardiovascular risk factors) is proportional to the magnitude of weight loss induced by lifestyle intervention, as well demonstrated in a substudy of the Look Ahead that quantified hepatic triglycerides by (1)H-MRS [23].”
BackgroundLifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis
Hohenester, S. D., Christiansen, S., Nagel, J. M., Wimmer, R., Artmann, R., Denk, G., Bischoff, M., Bischoff, G., & Rust, C. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2018 · Cited by 60
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease
Jeznach-Steinhagen, A. E., Ostrowska, J., Czerwonogrodzka–Senczyna, A., Boniecka, I., Shahnazaryan, U., & Kuryłowicz, A. (2019) · Medicina · doi:10.3390/medicina55050166 · Cited by 57
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 59
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Watanabe, H., Inaba, Y., Kimura, K., Asahara, S., Kido, Y., Matsumoto, M., Motoyama, T., Tachibana, N., Kaneko, S., Kohno, M., et al. (2016) · Journal of Nutrition · doi:10.3945/jn.116.231662 · Cited by 57
Xu, L., Nagata, N., & Ota, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235920 · Cited by 55
“The major lifestyle interventions are diet and exercise, with both dietary restriction and physical activity shown to reduce the risk of developing insulin resistance and NAFLD [37,38].”
BackgroundExercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease
Thorp, A., & Stine, J. G. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00543-9 · Cited by 50
Dua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 72
Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Parry, S. A., & Hodson, L. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01281-6 · Cited by 55
The urban built environment and adult BMI, obesity, and diabetes in Latin American cities
Anza‐Ramirez, C., Lazo, M., Zafra‐Tanaka, J. H., Ávila-Palència, I., Bilal, U., Hernández‐Vásquez, A., Knoll, C., López‐Olmedo, N., Mazariegos, M., Moore, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35648-w · Cited by 60
Self-citationPlant-Based Foods as a Source of Lipotropes for Human Nutrition: A Survey of In Vivo Studies
Fardet, A., & Chardigny, J. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2010.549596 · Cited by 52
“It was recently reported that up to 20–30% of adults among general adult population have hepatic steatosis (Lazo et al, 2010 ).”
Background(2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00019 · Cited by 46
Vahid, F., Hekmatdoost, A., Mirmajidi, S., Doaei, S., Rahmani, D., & Faghfoori, Z. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.06.008 · Cited by 49
Review of Treatment Options for Nonalcoholic Fatty Liver Disease
Corrado, R., Torres, D. M., & Harrison, S. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.001 · Cited by 45
Deibert, P., Lazaro, A., Schaffner, D., Berg, A., Koenig, D., Kreisel, W., Baumstark, M. W., Steinmann, D., Buechert, M., & Lange, T. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i9.1116 · Cited by 44
NAFLD, Estrogens, and Physical Exercise: The Animal Model
Lavoie, J.-M., & Pighon, A. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2012/914938 · Cited by 46
“More recently, a 12-month intensive lifestyle intervention in patients with type 2 diabetes has been reported to reduce hepatic steatosis by as much as 25% [104].”
BackgroundAcquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Pallayová, M., & Taheri, S. (2014) · Clinical Obesity · doi:10.1111/cob.12068 · Cited by 47
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview
Dajani, A. I., & Abu-Hammour, A. (2016) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.178527 · Cited by 45
Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases
Espina, S., Deza, D. C., Monterde, V. B., Domper-Arnal, M. J., García, S. G., & Luè, A. (2023) · Nutrients · doi:10.3390/nu15153487 · Cited by 60
Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39
“In this regard, an overall weight loss of 5% has repeatedly been shown to reduce steatosis and improve NAFLD [23], whilst a weight loss of 10% will likely lead to NASH resolution and an improvement of at least 1 stage in fibrosis score [24].”
BackgroundIncretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 38
The Role of Lifestyle Change in the Prevention and Treatment of NAFLD
Centis, E., Marzocchi, R., Suppini, A., Grave, R., Villanova, N., Hickman, I. J., & Marchesini, G. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811319290008 · Cited by 42
Non-Alcoholic Fatty Liver Disease, an Overview.
Muhammad, A. (2019) · PubMed Central · Cited by 51
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 44
Management of Nonalcoholic Steatohepatitis
Mahady, S. E., & George, J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.003 · Cited by 40
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
Lomonaco, R., Chen, J., & Cusi, K. J. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419157 · Cited by 43
“Many studies indicate that lifestyle [Haufe et al. 2011; Lazo et al. 2010; Kantartzis et al. 2009; Kirk et al. 2009; Viljanen et al. 2009] intervention may normalize liver aminotransferases and improve hepatic steatosis measured either by US [Sreenivasa Baba et al. 2006; Suzuki et al. 2005; Hickman…”
BackgroundNourian, M., Askari, G., Golshiri, P., Miraghajani, M., Shokri, S., & Arab, A. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.04.004 · Cited by 36
Ghosh, A., Dutta, K., Bhatt, S. P., Gupta, R., Tyagi, K., Ansari, I. A., Venugopal, V. K., Mahajan, H., Pandey, R. M., Pandey, S., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac138 · Cited by 41
Halpern, B., Mancini, M. C., de Melo, M. E., Lamounier, R. N., Moreira, R. O., Carra, M. K., Kyle, T. K., Cercato, C., & Boguszewski, C. L. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000465 · Cited by 63
A natural history study of paediatric non-alcoholic fatty liver disease over 10 years
Draijer, L. G., Voorhoeve, M., Troelstra, M., Holleboom, A. G., Beuers, U. H., Kusters, M., Nederveen, A. J., Benninga, M. A., & Koot, B. G. P. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100685 · Cited by 52
Weight loss in the prevention and treatment of diabetes
Delahanty, L. M. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.07.022 · Cited by 39
Kishida, Y., Okubo, H., Ohno, H., Oki, K., & Yoneda, M. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1331-4 · Cited by 34
“However, the current standard treatment of NASH is limited to weight reduction through lifestyle interventions, including dietary modifications and bariatric surgery [6, 7].”
BackgroundMoreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 53
Cobbold, J., Raveendran, S., Peake, C. M., Anstee, Q. M., Yee, M. S., & Thursz, M. R. (2013) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100319 · Cited by 33
Hens, W., Taeymans, J., Cornelis, J., Gielen, J., Gaal, L. V., & Vissers, D. K. (2015) · Journal of Physical Activity and Health · doi:10.1123/jpah.2015-0560 · Cited by 39
Berkan‐Kawińska, A., & Piekarska, A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1683817 · Cited by 38
Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis
Jirapinyo, P., de Moura, D. T. H., Horton, L. C., & Thompson, C. C. (2020) · Clinical Endoscopy · doi:10.5946/ce.2019.181 · Cited by 32
“This evidence likely explains the findings that 1) at a TWL of 2%–5%, there was an improvement in HbA1c, SBP, and TG; 2) at a TWL of 5%–10%, there was an improvement in DBP and HDL; and 3) at a TWL of at least 10%, there was an improvement in non-alcoholic steatohepatitis histologic features.(17-19) In this study, AT…”
ResultPan, X.-T., Xie, X.-X., Peng, H.-W., Cai, X.-L., Li, H.-Q., Hong, Q.-Z., Wu, Y.-L., Lin, X., Xu, S., & Peng, X.-E. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00220 · Cited by 23
Golay, A., Brock, E., Gabriel, R., Konrad, T., Lalic, N. M., Laville, M., Mingrone, G., Petrie, J. R., Phan, T., Pietiläinen, K. H., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12114 · Cited by 34
Borel, A., Nazare, J., Baillot, A., Alméras, N., Tremblay, A., Bergeron, J., Poirier, P., & Després, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2016 · Cited by 36
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
Current management of non-alcoholic fatty liver disease
Lisboa, Q. C., COSTA, S. M. F., & Couto, C. A. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.09.872 · Cited by 32
Lorenzo, C., Hanley, A. J., Rewers, M., & Haffner, S. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2826-4 · Cited by 32
“Lifestyle intervention and treatment with rimonabant have also been shown to reduce liver fat content, adiposity and dyslipidaemia in individuals with and without diabetes [42, 43].”
BackgroundIncreasing liver fat is associated with progression of cardiovascular risk factors
Brunner, K. T., Pedley, A., Massaro, J. M., Hoffmann, U., Benjamin, E. J., & Long, M. T. (2020) · Liver International · doi:10.1111/liv.14472 · Cited by 28
Lai, Y., He, Z., Liu, Y., Yin, X., Fan, X., Rao, Z., Fu, H., Gu, L., & Xia, T. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1231240 · Cited by 34
dos Reis, T. O., Ferolla, S. M., Lima, M. L. P., Fausto, M. A., Albricker, A. C. L., Armiliato, G. N. D. A., Camelo, C. G., Gomes, L. P. H., Ferrari, T. C. A., & Couto, C. A. (2015) · Medical Express · doi:10.5935/medicalexpress.2015.02.04 · Cited by 27
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., Neto, J. M. D. A., & Bertoluci, M. C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01259-2 · Cited by 34
“• In the Look AHEAD study, which included people with T2D, an average weight reduction of 8% with LSM resulted in a significant reduction in liver fat, assessed by magnetic resonance, compared with that in the control group [29].”
BackgroundState of the art: treatment of nonalcoholic steatohepatitis
Pearlman, M. Y., & Loomba, R. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000060 · Cited by 27
Portillo-Sánchez, P., Yavuz, S., Bril, F., & Cusi, K. J. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0229-3 · Cited by 26
The use of lorcaserin in the management of obesity: a critical appraisal
Wang, Y., & Bai (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s11945 · Cited by 27
“Weight loss has also been shown to improve liver function in patients with nonalcoholic fatty liver disease.(10,11) Unfortunately, failure to maintain changes in diet and exercise patterns is a major reason for weight regain experienced in most people.”
Wang, X., Zhao, B., Sun, H., You, H., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.866189 · Cited by 27
Okubo, H., Nakatsu, Y., Sakoda, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Matsunaga, Y., Ohno, H., Yoneda, M., Kamata, H., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00198.2014 · Cited by 23
Psychological and Psychiatric Aspects of Treatment of Obesity and Nonalcoholic Fatty Liver Disease
Stewart, K. E., & Levenson, J. L. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.007 · Cited by 24
“For example, fewer than 50%of individuals in 2 randomized clinical behavioral weight-loss trials in NAFLD achieved the 7%weight loss associated with improved outcomes.(14,15) Weight loss following bariatric surgery is maximal at 1 year, at which point progressive weight regain commonly begins (eg, 38% 7% of initial bo…”
BackgroundNonalcoholic Fatty Liver Disease
Gawrieh, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_14 · Cited by 25
Zhong, L. X., Jin, P., Liu, Y., Zhang, Z., Wu, X., Weng, M., Cao, S., Wang, Y., Zeng, C., Yang, R., et al. (2024) · Nutrition Journal · doi:10.1186/s12937-024-00968-8 · Cited by 28
“This comprehensive approach has been proven to result in significant weight reduction and reduce the risk of liver fibrosis, type 2 diabetes, and other metabolic diseases in adults with NAFLD with obesity or glucose abnormalities [16, 20–22].”
BackgroundAkbari, S., Sohouli, M. H., Ebrahimzadeh, S., Mansour‐Ghanaei, F., Hosseini, A. F., & Aryaeian, N. (2022) · Phytotherapy Research · doi:10.1002/ptr.7446 · Cited by 23
“activity during 6–12 months induces improvement in AST/ALT and GGT levels and metabolic (fasting glucose and insulin sensitivity) parameters, improved intrahepatic triacylglycerol concentrations, and reduced steatosis and inflammation, including ballooning and fibrosis detected in paired liver biopsies (Eckard et al.,…”
BackgroundFranco, I., Bianco, A., Díaz, M. D. P., Bonfiglio, C., Chiloiro, M., Pou, S. A., Coquet, J. B., Mirizzi, A., Nitti, A., Campanella, A., et al. (2019) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v76.n1.21638 · Cited by 20
Gerber, L. H., Weinstein, A. A., & Pawloski, L. R. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.016 · Cited by 22
Bischoff, M., Zimny, S., Feiner, S., Sauter, J., Sydor, S., Denk, G., Nagel, J. M., Bischoff, G., Rust, C., & Hohenester, S. D. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02846-7 · Cited by 21
Pharmacogenomic and Personalized Approaches to Tackle Nonalcoholic Fatty Liver Disease
Lorbek, G., Urlep, Ž., & Rozman, D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0047 · Cited by 21
Stine, J. G., Schreibman, I., Navabi, S., Kang, M., Dahmus, J., Soriano, C., Rivas, G., Hummer, B., Beyer, M., Tressler, H., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100560 · Cited by 19
Dietary treatment of nonalcoholic steatohepatitis
Perito, E. R., Rodríguez, L. A., & Lustig, R. H. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835ca11d · Cited by 22
“In a 12-month trial of adults with type 2 diabetes, losing 1–5% of body weight reduced hepatic steatosis by 33% compared with a 65% reduction in those who lost 5–10% body weight and 80% reduction in those that lost more than 10% [33].”
BackgroundGeng, T., Xia, L., Russo, S. B., Kamara, D., & Cowart, L. A. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.06.012 · Cited by 18
“Although physical activity and weight loss are effective measures for reducing liver fat [4], emerging data indicate that compared with saturated fat/fatty acids (SFA), dietary unsaturated fat high in n-6 polyunsaturated fatty acid (PUFA) can reduce liver fat and improve the metabolic status without weight loss [5].”
BackgroundPlauth, M., Schütz, T., Pirlich, M., Canbay, A. E., & Arends, J. (2014) · Aktuelle Ernährungsmedizin · doi:10.1055/s-0033-1360016 · Cited by 23
Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep’s Clothing?
Mitsala, A., Tsalikidis, C., Romanidis, Κ., & Pitiakoudis, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29070356 · Cited by 23
“Indeed, recent studies showed that a healthy diet and exercise could improve liver fat as assessed by US and MRI among NAFLD patients [145,146].”
BackgroundThe Look AHEAD Study: Implications for Clinical Practice Go Beyond the Headlines
Delahanty, L. M. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.01.008 · Cited by 20
“8% in diabetes support and education.(18) Greater weight loss in this subgroup (n1⁄496) was associated with larger decreases in steatosis; those who had weight loss of 10% had a significantly higher mean reduction in steatosis of 79.”
Qi, Y., Fan, L., Ran, D., Xu, J., Wang, Y., Wu, J., & Zhang, Z. (2021) · Journal of Oncology · doi:10.1155/2021/7764817 · Cited by 22
“A multicenter clinical trial involving 5145 overweight adults with T2DM showed that, after 12 months of intensive lifestyle intervention, steatosis and NAFLD were significantly reduced, and weight loss was at least 7% [51].”
BackgroundRiekki, H., Aitokari, L., Kivelä, L., Lahti, S., Hiltunen, P., Vuorela, N., Huhtala, H., Lakka, T. A., & Kurppa, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1090344 · Cited by 27
Leroux‐Stewart, J., Elisha, B., Tagougui, S., Suppère, C., Bernard, S., Mircescu, H., Desjardin, K., Messier, V., Iacobellis, G., & RABASA-LHORET, R. P. R. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.005 · Cited by 28
Management of Non-alcoholic Fatty Liver Disease
Leem, J., & Koh, E. H. (2014) · Journal of Korean Diabetes · doi:10.4093/jkd.2014.15.2.93 · Cited by 16
Abdelbasset, W. K., ELSAYED, S. H., Nambi, G. S., Alrawaili, S. M., Elnegamy, T. E., Khalil, M. A., Tantawy, S. A., Soliman, G. S., Ibrahim, A. A., & Kamel, D. M. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1923575 · Cited by 19
“Exercise training and dietary control reduce IHTG and improve metabolic function in patients with NAFLD [10, 11].”
BackgroundRetractedDietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician’s Guide
Aboubakr, A., Stroud, A., Kumar, S. R., & Newberry, C. A. (2021) · Current Gastroenterology Reports · doi:10.1007/s11894-021-00827-0 · Cited by 17
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
Miller, M. H., Bradford, V., & Dillon, J. F. (2013) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s34472 · Cited by 21
Metadata
- Authors
- Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., & for the Fatty Liver Subgroup of the Look AHEAD Research Group
- Affiliations
- Johns Hopkins University (US)
- Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;
- Duke Medical Center (US)
- Wake Forest University Health Sciences (US)
- Division of Endocrinology, Diabetes and Nutrition, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York;
- University of Washington (US)
- Corresponding author
- Lazo, Mariana
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-07-27
- Volume
- 33
- Issue
- 10
- Pages
- 2156-2163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2945152
- OpenAlex
- W2086657936
- Cited by
- 367
- References
- 24
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 17 · 2023: 18 · 2022: 26 · 2021: 27 · 2020: 31 · 2019: 24 · 2018: 15 · 2017: 17 · 2016: 35 · 2015: 23 · 2014: 26 · 2013: 29 · 2012: 22
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Johns Hopkins University (M01-RR-00052)
- National Institutes of Health (RR-00052)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57149, U01DK57149, U01DK057149, P30DK079637, R01DK060427)
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, non-alcoholic fatty liver disease, hepatic steatosis, intensive lifestyle intervention, weight loss, Look AHEAD trial, 1H NMR, diabetes support and education, glycemic control
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Life Style, Male, Middle Aged, Weight Loss, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
